These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 9107385

  • 1. Inhibition of human immunodeficiency virus type 1 infection in vitro by combination of delavirdine, zidovudine and didanosine.
    Chong KT, Pagano PJ.
    Antiviral Res; 1997 Mar; 34(1):51-63. PubMed ID: 9107385
    [Abstract] [Full Text] [Related]

  • 2. HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine.
    Demeter LM, Meehan PM, Morse G, Gerondelis P, Dexter A, Berrios L, Cox S, Freimuth W, Reichman RC.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Feb 01; 14(2):136-44. PubMed ID: 9052722
    [Abstract] [Full Text] [Related]

  • 3. Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients.
    Davey RT, Chaitt DG, Reed GF, Freimuth WW, Herpin BR, Metcalf JA, Eastman PS, Falloon J, Kovacs JA, Polis MA, Walker RE, Masur H, Boyle J, Coleman S, Cox SR, Wathen L, Daenzer CL, Lane HC.
    Antimicrob Agents Chemother; 1996 Jul 01; 40(7):1657-64. PubMed ID: 8807058
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life.
    Kovacs A, Cowles MK, Britto P, Capparelli E, Fowler MG, Moye J, McIntosh K, Rathore MH, Pitt J, Husson RN.
    Pediatr Infect Dis J; 2005 Jun 01; 24(6):503-9. PubMed ID: 15933559
    [Abstract] [Full Text] [Related]

  • 5. Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor.
    Freimuth WW.
    Adv Exp Med Biol; 1996 Jun 01; 394():279-89. PubMed ID: 8815692
    [Abstract] [Full Text] [Related]

  • 6. In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication.
    Perez-Olmeda M, Garcia-Perez J, Mateos E, Spijkers S, Ayerbe MC, Carcas A, Alcami J.
    J Med Virol; 2009 Feb 01; 81(2):211-6. PubMed ID: 19107982
    [Abstract] [Full Text] [Related]

  • 7. Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370.
    Kuritzkes DR, Bassett RL, Johnson VA, Marschner IC, Eron JJ, Sommadossi JP, Acosta EP, Murphy RL, Fife K, Wood K, Bell D, Martinez A, Pettinelli CB.
    AIDS; 2000 Jul 28; 14(11):1553-61. PubMed ID: 10983642
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). ACTG 261 Team.
    Friedland GH, Pollard R, Griffith B, Hughes M, Morse G, Bassett R, Freimuth W, Demeter L, Connick E, Nevin T, Hirsch M, Fischl M.
    J Acquir Immune Defic Syndr; 1999 Aug 01; 21(4):281-92. PubMed ID: 10428106
    [Abstract] [Full Text] [Related]

  • 9. Zidovudine therapy and HIV type 1 mutations in children with symptomatic HIV type 1 infection: effect of switching to didanosine or zidovudine plus didanosine therapy. Italian Multicenter Study Group on HIV Mutations in Children.
    Principi N, Marchisio P, Esposito S, Rossi P, Gattinara GC, Galli L, Gabiano C, Zuccotti GV, Orlandi P.
    AIDS Res Hum Retroviruses; 1998 Dec 20; 14(18):1653-9. PubMed ID: 9870319
    [Abstract] [Full Text] [Related]

  • 10. Pharmacodynamic studies (PD) of didanosine (ddI) alone and in combination with azidothymidine (AZT) in human T-cells; a stochastic biochemical approach to antiretroviral nucleoside drug combination in inhibiting HIV-reverse transcriptase (RT).
    Periclou AP, Nandy P, Avramis VI.
    In Vivo; 2000 Dec 20; 14(3):377-88. PubMed ID: 10904870
    [Abstract] [Full Text] [Related]

  • 11. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.
    Izopet J, Bicart-See A, Pasquier C, Sandres K, Bonnet E, Marchou B, Puel J, Massip P.
    J Med Virol; 1999 Dec 20; 59(4):507-11. PubMed ID: 10534734
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of human immunodeficiency virus type 1 replication in vitro by the bisheteroarylpiperazine atevirdine (U-87201E) in combination with zidovudine or didanosine.
    Campbell TB, Young RK, Eron JJ, D'Aquila RT, Tarpley WG, Kuritzkes DR.
    J Infect Dis; 1993 Aug 20; 168(2):318-26. PubMed ID: 7687641
    [Abstract] [Full Text] [Related]

  • 13. Greater and more rapid depletion of mitochondrial DNA in blood of patients treated with dual (zidovudine+didanosine or zidovudine+zalcitabine) vs. single (zidovudine) nucleoside reverse transcriptase inhibitors.
    Reiss P, Casula M, de Ronde A, Weverling GJ, Goudsmit J, Lange JM.
    HIV Med; 2004 Jan 20; 5(1):11-4. PubMed ID: 14731163
    [Abstract] [Full Text] [Related]

  • 14. Didanosine (ddI) and zidovudine (ZDV) susceptibilities of human immunodeficiency virus (HIV) isolates from long-term recipients of ddI.
    Reichman RC, Tejani N, Lambert JL, Strussenberg J, Bonnez W, Blumberg B, Epstein L, Dolin R.
    Antiviral Res; 1993 Apr 20; 20(4):267-77. PubMed ID: 8097906
    [Abstract] [Full Text] [Related]

  • 15. Vitamin D attenuates nucleoside reverse transcriptase inhibitor induced human skeletal muscle mitochondria DNA depletion.
    Campbell GR, Pallack ZT, Spector SA.
    AIDS; 2013 Jun 01; 27(9):1397-401. PubMed ID: 23435299
    [Abstract] [Full Text] [Related]

  • 16. Genotypic resistance to zidovudine as a predictor of failure of subsequent therapy with human immunodeficiency virus type-1 nucleoside reverse-transcriptase inhibitors.
    Venturi G, Romano L, Catucci M, Riccio ML, De Milito A, Gonnelli A, Rubino M, Valensin PE, Zazzi M.
    Eur J Clin Microbiol Infect Dis; 1999 Apr 01; 18(4):274-82. PubMed ID: 10385016
    [Abstract] [Full Text] [Related]

  • 17. Antiviral roundup.
    Smart T, Torres G.
    GMHC Treat Issues; 1996 Aug 01; 10(8):6-7. PubMed ID: 11363720
    [Abstract] [Full Text] [Related]

  • 18. Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection.
    Morse GD, Fischl MA, Shelton MJ, Cox SR, Driver M, DeRemer M, Freimuth WW.
    Antimicrob Agents Chemother; 1997 Jan 01; 41(1):169-74. PubMed ID: 8980774
    [Abstract] [Full Text] [Related]

  • 19. FDA advisory committee deadlocks on delavirdine. Food and Drug Administration.
    Mascolini M.
    AIDS Treat News; 1996 Dec 06; (No 260):3-5. PubMed ID: 11364022
    [Abstract] [Full Text] [Related]

  • 20. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team.
    McKinney RE, Johnson GM, Stanley K, Yong FH, Keller A, O'Donnell KJ, Brouwers P, Mitchell WG, Yogev R, Wara DW, Wiznia A, Mofenson L, McNamara J, Spector SA.
    J Pediatr; 1998 Oct 06; 133(4):500-8. PubMed ID: 9787687
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.